Business
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 ...
About this update from Bausch Health Companies Inc.
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basisFull-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basisFull-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for the yearAdjusted EBITDA Attributable to Bausch Health Companies Inc. 1 of $869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior yearLAVAL, QC / ACCESSWIRE / February 22, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results."I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success," said Thomas J. Appio, Chief Executive Officer, Bausch Health.Bausch Health (excl. B+L) R&D UpdateAmiselimod (S1P modulator): once-daily oral treatment of mild to moderate ulcerative colitisPhase 2 study completed enrollment in July 2023 and positive topline data results announced in December 2023RED-C : prevention and delay of first episode of hepatic encephalopathyEnrollment of one of two global Phase 3 trials completed, with enrollment of the second trial on track and expected to be completed in the first half of 2024___________________________________1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the most directly ...
View stock analysis, news, and events for Bausch Health Companies Inc.